Charles River provides lab research services and animal models for drug development.
Charles River Laboratories International, Inc. (CRL) is expected to report earnings on Wednesday, November 4, 2026, before the open. Estimated release time 07:15 ET. Consensus EPS estimate is $2.97.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | Jun 2026 qtr | $2.74 | $3.02 | +10.2% | $1.00B |
| 2026-05-07 | Mar 2026 qtr | $1.96 | $2.06 | +5.1% | $995.83M |
| 2026-02-18 | Dec 2025 qtr | $2.33 | $2.39 | +2.6% | $994.23M |
| 2025-11-05 | Sep 2025 qtr | $2.32 | $2.43 | +4.7% | $1.00B |
| 2025-08-06 | Jun 2025 qtr | $2.50 | $3.12 | — | $1.03B |
| 2025-05-07 | Mar 2025 qtr | $2.06 | $2.34 | +13.6% | $984.17M |
| 2025-02-19 | Dec 2024 qtr | $2.50 | $2.66 | +6.4% | $1.00B |
| 2024-11-06 | Sep 2024 qtr | $2.42 | $2.59 | +7.0% | $1.01B |
CRL has beaten consensus EPS in 7 of its last 7 scored quarters.
See CRL on the live calendar →